Integrated genomic approaches identify upregulation of SCRN1 as a novel mechanism associated with acquired resistance to erlotinib in PC9 cells harboring oncogenic EGFR mutation.

导出 OA

翻译打印收藏纠错

作者： Nayoung,Kim ^[1] ; Ahye,Cho ^[2] ; Hideo,Watanabe ^[2] ; Yoon-La,Choi ^[3] ; Meraj,Aziz ^[4] ; Michelle,Kassner ^[2] ; Je-Gun,Joung ^[5] ; Angela Kyung-Joo,Park ^[6] ; Joshua M,Francis ^[6] ; Joon Seol,Bae ^[7] ; Soo-Min,Ahn ^[1] ; Kyoung-Mee,Kim ^[2] ; Joon Oh,Park ^[8] ; Woong-Yang,Park ^[7] ; Myung-Ju,Ahn ^[5] ; Keunchil,Park ^[5] ; Jaehyung,Koo ^[9] ; Hongwei Holly,Yin ^[2] ; Jeonghee,Cho ^[7]

作者单位： Department of NanoBio Medical Science, Dankook University, Cheonan 31116, Republic of Korea. ^[1] Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul 135-967, Republic of Korea. ^[2] Department of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, New York, NY 10029, USA. ^[3] Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. ^[4] Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 135-967, Republic of Korea. ^[5] Cancer and Cell Biology Division, Translational Genomics Research Institute, Scottsdale, AZ 85259, USA. ^[6] Samsung Genome Institute, Samsung Medical Center, Seoul 135-967, Republic of Korea. ^[7] Cancer Program, Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA. ^[8] Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 135-967, Republic of Korea. ^[9] Department of Brain and Cognitive Sciences, DGIST, Daegu 42988, Republic of Korea. ^[10]

关键词 EGFR SCRN1 erlotinib resistance lung adenocarcinoma